Aligos Therapeutics (ALGS) News Today $18.63 -2.22 (-10.65%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$19.14 +0.52 (+2.76%) As of 02/21/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Decrease in Short InterestAligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) saw a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 576,400 shares, a drop of 13.2% from the January 15th total of 664,400 shares. Based on an average daily trading volume, of 462,000 shares, the days-to-cover ratio is currently 1.2 days. Approximately 21.8% of the shares of the company are short sold.February 17, 2025 | marketbeat.comAligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Down 13.2% in JanuaryFebruary 17, 2025 | americanbankingnews.comAligos Therapeutics announces $105M private placement financingFebruary 12, 2025 | markets.businessinsider.comAligos Therapeutics secures $105 million in private placementFebruary 12, 2025 | msn.comAligos Therapeutics Announces $105 Million Private Placement FinancingFebruary 12, 2025 | globenewswire.comHere's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash WiselyFebruary 8, 2025 | finance.yahoo.comAligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Increase in Short InterestAligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 597,300 shares, a growth of 30.7% from the December 31st total of 457,100 shares. Based on an average daily volume of 421,900 shares, the days-to-cover ratio is presently 1.4 days. Approximately 22.4% of the shares of the company are short sold.January 30, 2025 | marketbeat.comDrive Wealth Management LLC Acquires New Holdings in Aligos Therapeutics, Inc. (NASDAQ:ALGS)Drive Wealth Management LLC bought a new position in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 23,000 shares of the company's stock, valued at approximately $916,000. Drive Wealth ManJanuary 27, 2025 | marketbeat.comAligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Growth in Short InterestAligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 597,300 shares, an increase of 30.7% from the December 15th total of 457,100 shares. Currently, 22.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 421,900 shares, the days-to-cover ratio is currently 1.4 days.January 16, 2025 | marketbeat.comAligos Therapeutics, Inc.'s (NASDAQ:ALGS) biggest owners are retail investors who got richer after stock soared 17% last weekDecember 21, 2024 | finance.yahoo.comCharles Schwab Investment Management Inc. Lowers Stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS)Charles Schwab Investment Management Inc. cut its position in Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) by 61.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,980 shareDecember 21, 2024 | marketbeat.comAligos Therapeutics announces inducement grants under Nasdaq listing ruleDecember 14, 2024 | markets.businessinsider.comAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 13, 2024 | globenewswire.comAligos Therapeutics: Promising Pipeline With Cash And Dilution RisksDecember 11, 2024 | seekingalpha.comBaker BROS. Advisors LP Has $719,000 Position in Aligos Therapeutics, Inc. (NASDAQ:ALGS)Baker BROS. Advisors LP lessened its stake in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) by 96.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 83,055 shares of the company's stockDecember 2, 2024 | marketbeat.comAligos Therapeutics to Present at Investor Conferences in DecemberNovember 26, 2024 | markets.businessinsider.comAligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024November 19, 2024 | globenewswire.comAligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Growth in Short InterestAligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) saw a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 121,300 shares, an increase of 46.5% from the October 15th total of 82,800 shares. Based on an average daily volume of 145,700 shares, the short-interest ratio is currently 0.8 days. Approximately 4.8% of the company's stock are sold short.November 14, 2024 | marketbeat.comAligos Therapeutics trading halted, volatility trading pauseNovember 12, 2024 | markets.businessinsider.comAligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial ResultsNovember 6, 2024 | globenewswire.comAligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Drop in Short InterestAligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) was the target of a large decrease in short interest in October. As of October 15th, there was short interest totalling 82,800 shares, a decrease of 31.0% from the September 30th total of 120,000 shares. Currently, 3.7% of the company's stock are sold short. Based on an average daily volume of 62,300 shares, the days-to-cover ratio is currently 1.3 days.October 27, 2024 | marketbeat.comAligos Therapeutics (NASDAQ:ALGS) Shares Down 5.4% - What's Next?Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 5.4% - Here's What HappenedOctober 25, 2024 | marketbeat.comAligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading Volume - Should You Buy?Aligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading Volume - Here's What HappenedOctober 24, 2024 | marketbeat.comAligos Therapeutics’ Promising Clinical Advancements and Buy Rating Driven by Strong Market PotentialOctober 24, 2024 | markets.businessinsider.comAligos Therapeutics (NASDAQ:ALGS) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $75.00 price objective on shares of Aligos Therapeutics in a research note on Wednesday.October 23, 2024 | marketbeat.comAligos announces FDA cleared IND for Phase 1 DDI study of ALG-000184October 23, 2024 | markets.businessinsider.comAligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184October 22, 2024 | finance.yahoo.comAligos Therapeutics (NASDAQ:ALGS) Shares Gap Up - Here's What HappenedAligos Therapeutics (NASDAQ:ALGS) Shares Gap Up - What's Next?October 15, 2024 | marketbeat.comAligos Therapeutics (NASDAQ:ALGS) Trading Down 8.4% - Should You Sell?Aligos Therapeutics (NASDAQ:ALGS) Shares Down 8.4% - Here's What HappenedOctober 14, 2024 | marketbeat.comAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 11, 2024 | globenewswire.comAligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading Volume - Still a Buy?Aligos Therapeutics (NASDAQ:ALGS) Sees Large Volume Increase - Time to Buy?October 10, 2024 | marketbeat.comAligos Therapeutics appoints new VP of Business DevelopmentOctober 3, 2024 | uk.investing.comAligos Therapeutics (NASDAQ:ALGS) Shares Down 6.2% Aligos Therapeutics (NASDAQ:ALGS) Shares Down 6.2%October 3, 2024 | marketbeat.comAligos Therapeutics Appoints David Perry as Vice President of Business DevelopmentOctober 1, 2024 | globenewswire.comAligos Therapeutics to Present at Investor Conferences in OctoberSeptember 30, 2024 | globenewswire.comPiper Sandler Sticks to Their Buy Rating for Aligos Therapeutics (ALGS)September 25, 2024 | markets.businessinsider.comAligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical OfficerSeptember 24, 2024 | markets.businessinsider.comAligos Therapeutics (NASDAQ:ALGS) Sees Large Volume IncreaseAligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading VolumeSeptember 24, 2024 | marketbeat.comAligos Therapeutics (NASDAQ:ALGS) Reaches New 52-Week Low at $8.28Aligos Therapeutics (NASDAQ:ALGS) Hits New 12-Month Low at $8.28September 23, 2024 | marketbeat.comBuy Recommendation: Aligos Therapeutics’ ALG-055009 Shows Promise in Phase 2a with Advancement and Partnership PotentialSeptember 21, 2024 | markets.businessinsider.comAligos Therapeutics (NASDAQ:ALGS) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $75.00 price objective on shares of Aligos Therapeutics in a research report on Friday.September 20, 2024 | marketbeat.comAligos' fatty liver disease treatment meets main goal in mid-stage studySeptember 20, 2024 | reuters.comAligos posts initial mid-stage trial results for MASH candidateSeptember 20, 2024 | msn.comAligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASHSeptember 19, 2024 | globenewswire.comAligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024September 18, 2024 | globenewswire.comInvenra Welcomes Three Industry Leaders to Its Board of DirectorsSeptember 17, 2024 | businesswire.comAligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 18.3% in AugustAligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 14,900 shares, a growth of 18.3% from the August 15th total of 12,600 shares. Based on an average trading volume of 34,700 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.7% of the company's shares are short sold.September 15, 2024 | marketbeat.comAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 13, 2024 | globenewswire.comAligos Therapeutics (NASDAQ:ALGS) Stock Price Up 12.3%Aligos Therapeutics (NASDAQ:ALGS) Trading 12.3% HigherSeptember 12, 2024 | marketbeat.comAligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $13.79Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $13.79September 11, 2024 | marketbeat.com Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Email Address ALGS Media Mentions By Week ALGS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALGS News Sentiment▼1.420.60▲Average Medical News Sentiment ALGS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALGS Articles This Week▼21▲ALGS Articles Average Week Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Taysha Gene Therapies News Today Cryoport News Today Annexon News Today Corvus Pharmaceuticals News Today Trevi Therapeutics News Today COMPASS Pathways News Today Aquestive Therapeutics News Today Gossamer Bio News Today Candel Therapeutics News Today Atyr PHARMA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALGS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
